NCT04856293 - Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions

Healthy Participants

Interventions

DRUG

Crizotinib

A single 250 mg crizotinib dose of the FC formulation

DRUG

Crizotinib

A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial

DRUG

Crizotinib

A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven